Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Yue ZhaoZheyi HuSai Praneeth BathenaSarah KeidelKaren Miller-MoslinPaul StatkevichAkintunde BelloAmit RoySatyendra SuryawanshiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The CPP of relatlimab alone or in combination with nivolumab supports the approved dosing in advanced melanoma and the continued evaluation of nivolumab and relatlimab across other solid tumors. See related commentary by Gopalakrishnan and Amaria, p. 2862.